13 completed, 7 terminated, 4 unknown, 3 withdrawn. 30 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 13, Terminated 7, Unknown 4, Withdrawn 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Lovastatin: new trials by email Literature Review of Lovastatin trials Research Report on Lovastatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-10-31 | 2026-09-22 |
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| Lovastatin for Treatment of Brain Arteriovenous Malformations Lovastatin, Placebo - Cerebral Arteriovenous Malformation | Phase 2 | Unknown | Beijing Tiantan Hospital | 1244 | 2021-01-01 | 2020-03-09 |
| Synaptic Plasticity and Cognitive Function in RASopathies Lovastatin, Lamotrigine - Impaired Synaptic Plasticity, Impaired Cognition | Phase 2 | Terminated | Technical University of Munich | 16 | 2019-03-22 | 2023-11-30 |
| Efficacy and Safety of SYN-010 in IBS-C SYN-010 21 mg, SYN-010 42 mg, Placebo - Irritable Bowel Syndrome With Constipation | Phase 2 | Terminated | Cedars-Sinai Medical Center | 59 | 2018-12-24 | 2022-07-13 |
| Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Lovastatin in the Preservation of the Tooth Socket Lovastatin 40 MG, without drug with Bone graft - Bone Loss | Phase 2 | Unknown | Islamic Azad University, Sanandaj | 20 | 2018-02-22 | 2019-06-11 |
| Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease Lovastatin, Placebo - Parkinson Disease | Phase 2 | Unknown | National Taiwan University Hospital | 80 | 2017-05-15 | 2017-10-17 |
| Interventions for Reading Disabilities in NF1 Lovastatin, reading tutoring intervention, Placebo Oral Tablet - Neurofibromatosis Type 1, Learning Disability | Phase 2 | Active not recruiting | Vanderbilt University | 120 | 2016-11-01 | 2026-07-01 |
| Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome Minocycline, then Minocycline/Lovastatin, Lovastatin, then Minocycline/Lovastatin - Fragile X Syndrome | Phase 2 | Completed | Université de Sherbrooke | 22 | 2016-03-01 | 2018-10-15 |
| Pharmacological Treatment of Rett Syndrome With Statins Lovastatin - Rett Syndrome | Phase 2 | Completed | Montefiore Medical Center | 20 | 2015-07-01 | 2019-07-12 |
| Effects of Lovastatin on Human Platelet Proteome Lovastatin - Blood Platelets Proteome | Phase 2 | Completed | Université de Sherbrooke | 15 | 2015-02-01 | 2015-06-16 |
| A Study of LY3015014 in Participants With High Cholesterol LY3015014, Placebo, Statin - Hypercholesterolemia | Phase 2 | Completed | Eli Lilly and Company | 527 | 2013-06-01 | 2019-09-18 |
| Novel Treatment for Syndromic Ichthyoses Lovastatin - Syndromic Ichthyoses, CHILD Syndrome | Phase 2 | Withdrawn | Northwestern University | 2011-07-01 | 2015-05-19 | |
| Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma lovastatin, interferon alfa-2b - Melanoma, Malignant Melanoma | Phase 2 | Withdrawn | NeoPlas Innovation | 250 | 2009-12-01 | 2009-09-09 |
| A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Lovastatin ™, placebo - Neurofibromatosis Type 1 | Phase 2 | Completed | University of Alabama at Birmingham | 146 | 2009-07-01 | 2018-03-12 |
| Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer lovastatin, questionnaire administration, adjuvant therapy - Breast Cancer, Radiation Toxicity | Phase 2 | Terminated | Virginia Commonwealth University | 3 | 2009-04-01 | 2013-06-20 |
| Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 Low Dose Lovastatin, Placebo, High Dose Lovastatin - Stroke, Rhabdomyolysis | Phase 2 | Completed | Columbia University | 162 | 2009-02-01 | 2025-12-01 |
| Lovastatin: Immunomodulatory Value Evaluation Lovastatin, placebo - HIV Seropositivity | Phase 2 | Completed | Universidad de Antioquia | 112 | 2008-08-01 | 2011-10-04 |
| Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD) Lovastatin, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | National Jewish Health | 30 | 2008-04-01 | 2021-01-19 |
| Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis Lovastatin, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 64 | 2007-11-06 | 2022-09-07 |
Showing 20 of 30. Sign in to see all of them.
Breast Neoplasms (3) · Neurofibromatosis 1 (3) · Atherosclerosis (2) · Cardiovascular Diseases (2) · Heart Diseases (2) · Hypercholesterolemia (2) · Melanoma (2) · Arthritis, Rheumatoid (1) · Asthma (1) · Autistic Disorder (1) · Bone Diseases, Metabolic (1) · Breast Carcinoma In Situ (1) · Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Carotid Stenosis (1)
National Heart, Lung, and Blood Institute (NHLBI) (2) · University of Iowa (2) · Université de Sherbrooke (2) · Virginia Commonwealth University (2) · Beijing Tiantan Hospital (1) · Cedars-Sinai Medical Center (1) · Columbia University (1) · Eli Lilly and Company (1) · Emory University (1) · Islamic Azad University, Sanandaj (1) · Merck Sharp & Dohme LLC (1) · Montefiore Medical Center (1) · National Cancer Institute (NCI) (1) · National Center for Research Resources (NCRR) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (18) · Canada (3) · Australia (1) · China (1) · Colombia (1) · Czechia (1) · Denmark (1) · Germany (1) · Iran (1) · Japan (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Taiwan (1)
Raymond Hohl, MD (2) · Aleksandra Djukic, MD PhD (1) · Ali Rezaie, MD MSc (1) · Amy S Paller, MD (1) · Andrew A Davis, MD (1) · Betty Diamond, MD (1) · Blanca Camoretti-Mercado, Ph.D. (1) · Carlos J Montoya, MD, PhD (1) · Chin-Hsien Lin, MD, PhD (1) · Curt Furberg (1) · Cynthia Aranow, MD (1) · Donald Hunninghake (1) · E Rand Sutherland, MD, MPH (1) · Fabian A Jaimes, MD, PhD (1)
PMID 19538732, PMID 23085245, PMID 24166281, PMID 27956565, PMID 31628482, PMID 36114762, PMID 37280688, PMID 37565307, PMID 39248107, PMID 42254059
2016 (1), N01CN35160 (1), P30CA138292 (1), P50NS049060 (1), R01HD089474 (1), R01HL038194 (1), U01HL044315 (1), UL1RR024999 (1)